Living in Vienna as an expat, one of the things that becomes clear over time is how deliberately the city thinks about its role in the global economy. It rarely markets itself with grand claims, yet it consistently invests in the fundamentals. That’s why the first CEO Round Table on Life Sciences, organised by INVEST in AUSTRIA – Austrian Business Agency (ABA), feels like more than just another high-level discussion. It signals a quiet but important confidence in where Vienna—and Austria more broadly—can realistically compete.
The round table, hosted in Vienna, brought together business leaders, policymakers, and journalists to discuss Austria’s position in the global life sciences market. Life sciences are not a niche here; they are explicitly identified as a cornerstone of Austria’s Industry Strategy 2035, and for good reason. From pharmaceuticals and biotechnology to medical research and applied innovation, the sector sits at the intersection of science, regulation, talent, and long-term capital—areas where Austria has structural strengths, but also clear challenges.
What stood out to me was the composition of the discussion itself. Leaders such as Boehringer Ingelheim, represented by its Regional Center Vienna, sat alongside voices from economic policy, national media, and international biopharma through MSD Austria. The presence of the Federal Ministry for Economy, Energy and Tourism (BMWET) underscored that this was not an abstract conversation about innovation, but one rooted in policy realities—regulatory frameworks, investment conditions, and international competitiveness.
From an outsider’s perspective, Vienna’s appeal as a life sciences location lies in its balance. It offers a strong research ecosystem, a steady pipeline of highly skilled talent, and proximity to both Western and Central/Eastern European markets. At the same time, it operates within a regulatory environment that values stability and predictability. For global companies deciding where to place long-term research or regional headquarters, that combination can be more attractive than jurisdictions that move faster but change rules just as quickly.
That said, the challenges raised during the round table shouldn’t be understated. Competition for talent is global, regulatory processes can feel slow, and the gap between research excellence and commercial scaling still needs work. From living here, I see this tension daily: Vienna is exceptionally good at creating knowledge, but sometimes less confident in turning it into growth stories that resonate internationally. Events like this round table matter precisely because they create space to address those gaps openly.
What this initiative means for Vienna, in my view, is momentum—if it’s followed through. A continuous, solution-oriented platform that brings together industry, government, and media can help align priorities instead of fragmenting them. If Austria wants to strengthen its life sciences cluster over the next decade, it will need faster pathways from research to market, clearer signals to international investors, and an immigration and talent framework that keeps pace with global demand.
As an expat, I find it encouraging to see Vienna leaning into sectors where it can genuinely compete on quality rather than scale. Life sciences reward patience, collaboration, and trust—qualities that fit this city remarkably well. If the dialogue started by the ABA CEO Round Table translates into concrete policy adjustments and sustained collaboration, Vienna could quietly position itself as one of Europe’s most reliable life sciences hubs. Not the loudest, but perhaps one of the most durable.
